Mitogen-activated protein kinase pathway inhibitors:
inhibitors for diseases?

doi:10.1007/s11684-010-0010-0

Front. Med.

2010, Vol. 4

Issue (1) : 46-53 https://doi.org/10.1007/s11684-010-0010-0

Research articles

Mitogen-activated protein kinase pathway inhibitors: inhibitors for diseases?

Xu WANG MS¹,Xiao-Wei GONG MD, PhD²,Yong JIANG MD, PhD²,Yu-Hua LI PhD³,

1.College of Life Science, Northeast Forestry University, Harbin 150040, China；Key Laboratory of Functional Proteomics of Guangdong Province, Department of Pathophysiology, Southern Medical University, Guangzhou 510515, China; 2.Key Laboratory of Functional Proteomics of Guangdong Province, Department of Pathophysiology, Southern Medical University, Guangzhou 510515, China; 3.College of Life Science, Northeast Forestry University, Harbin 150040, China;

Download: PDF(258 KB)
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks

Abstract Mitogen-activated protein kinase (MAPK) signaling pathway, one of the most important signaling pathways in eukaryotic organism, is involved in multiple cellular events such as cell growth, differentiation, and apoptosis. MAPK is of great importance to the normal function of organisms, while its dysfunction results in various diseases. So far, inhibitors specifically against each subfamilies of MAP kinase have been developed, while more endeavors are needed to discover the compounds selectively targeting a particular subfamily member. Most of the kinase inhibitors exert their functions in an ATP-competitive way or a non-ATP-competitive way. Further studies on the effective mechanism of the MAPK inhibitors and their therapeutic roles in the treatment of diseases are helpful for the illumination of MAP kinase function, the development of novel inhibitors, and the therapy of diseases caused by the dysfunction of the MAPK pathway.

Keywords mitogen-activated protein kinase drug target inhibitor signal transduction disease

Issue Date: 05 March 2010

Cite this article:

Xu WANG MS,PhD,Xiao-Wei GONG MD, et al. Mitogen-activated protein kinase pathway inhibitors: inhibitors for diseases?[J]. Front. Med., 2010, 4(1): 46-53.

URL:

https://academic.hep.com.cn/fmd/EN/10.1007/s11684-010-0010-0
https://academic.hep.com.cn/fmd/EN/Y2010/V4/I1/46

	Widmann C, Gibson S, Jarpe M B, Johnson G L. Mitogen-activated protein kinase: conservation of a three-kinasemodule from yeast to human. Physiol Rev, 1999, 79(1): 143–180
	Gong X W, Jiang Y. Progressesin mitogen-activated protein kinase-activated protein kinases. Shengwuhuaxue Yu Shengwuwuli Jinzhan, 2007, 34(7): 1–7 (in Chinese)
	Gong X W, Wei J, Li Y S, Cheng W W, Deng P, Jiang Y. Involvement of p38 mitogen-activated protein kinase inthe regulation of platelet-derived growth factor-induced cell migration. Front Med China, 2007, 1(3): 248–252
	Jiang Y, Chen C, Li Z, Guo W, Gegner J A, Lin S, Han J. Characterization of the structureand function of a new mitogen-activated protein kinase (p38beta). J Biol Chem, 1996, 271(30): 17920–17926
	Ivanenkov Y A, Balakin K V, Tkachenko S E. New approaches to the treatmentof inflammatory disease: focus on small molecule inhibitors of signaltransduction pathways. Drugs R D, 2008, 9(6): 397–434
	Adcock I M, Caramori G, Chung K F. New targets for drug developmentin asthma. Lancet, 2008, 372(9643): 1073–1087
	Smith R A, Dumas J, Adnane L, Wilhelm S M. Recent advances in the research and development of RAF kinase inhibitors. Curr Top Med Chem, 2006, 6(11): 1071–1089
	VanScyoc W S, Holdgate G A, Sullivan J E, Ward W H. Enzyme kinetics and binding studies on inhibitors ofMEK protein kinase. Biochemistry, 2008, 47(17): 5017–5027
	Ohori M, Takeuchi M, Maruki R, Nakajima H, Miyake H. FR180204,a novel and selective inhibitor of extracellular signal-regulatedkinase, ameliorates collagen-induced arthritis in mice. Naunyn Schmiedebergs Arch Pharmacol, 2007, 374(4): 311–316
	Kelemen B R, Hsiao K, Goueli S A. Selective invivo inhibition of mitogen-activated protein kinase activationusing cell-permeable peptides. J Biol Chem, 2002, 277(10): 8741–8748
	Bogoyevitch M A, Boehm I, Oakley A, Ketterman A J, Barr R K. Targeting the JNK MAPK cascadefor inhibition: basic science and therapeutic potential. Biochim Biophys Acta, 2004, 1697(1―2): 89–101
	Bogoyevitch M A, Arthur P G. Inhibitors of c-Jun N-terminal kinases: JuNK no more? Biochim Biophys Acta, 2008, 1784(1): 76–93
	Scapin G, Patel S B, Lisnock J, Becker J W, LoGrasso P V. The structure of JNK3 incomplex with small molecule inhibitors. Chem Biol, 2003, 10(8): 705–712
	Carboni S, Boschert U, Gaillard P, Gotteland J P, Gillon J Y, Vitte P A. AS601245, a c-Jun NH2-terminalkinase (JNK) inhibitor, reduces axon/dendrite damage and cognitivedeficits after global cerebral ischemia in gerbils. Br J Pharmacol, 2008, 153(1): 157–163
	Barr R K, Boehm I, Attwood P V, Watt P M, Bogoyevitch M A. The critical features andthe mechanism of inhibition of a kinase interaction motif-based peptideinhibitor of JNK. J Biol Chem, 2004, 279(35): 36327–36338
	Holzberg D, Knight C G, Dittrich-Breiholz O, Schneider H, Dorrie A, Hoffmann E, Resch K, Kracht M. Disruptionof the c-JUN-JNK complex by a cell-permeable peptide containing thec-JNK delta domain induces apoptosis and affects a distinct set ofinterleukin-1-induced inflammatory genes. J Biol Chem, 2003, 278(41): 40213–40223
	Argast G M, Fausto N, Campbell J S. Inhibition of RIP2/Rick/CARDIAKactivity by pyridinyl imidazole inhibitors of p38 MAPK. Mol Cell Biochem, 2005, 268(1―2): 129–140
	Fitzgerald C E, Patel S B, Becker J W, Cameron P M, Zaller D, Pikounis V B, O’Keefe S J, Scapin G. Structural basis for p38αMAP kinase quinazolinone and pyridol-pyrimidine inhibitor specificity. Nat Struct Biol, 2003, 10(9): 764–769
	Cuenda A, Rousseau S. p38MAP-kinases pathway regulation, function and role in human diseases. Biochim Biophys Acta, 2007, 1773(8): 1358–1375
	Bullington J, Argentieri D, Averill K, Carter D, Cavender D, Fahmy B, Fan X, Hall D, Heintzelman G, Jackson P, Leung W P, Li X, Ling P, Olini G, Razler T, Reuman M, Rupert K, Russell R, Siekierka J, Wadsworth S, Wolff R, Xiang B, Zhang Y M. Inhibitors of unactivated p38 MAP kinase. Bioorg Med Chem Lett, 2006, 16(23): 6102–6106
	Pargllis C, Tong L, Churchill L, Cirillo P F, Gilmore T, Graham A G, Grob P M, Hickey E R, Moss N, Pav S, Regan J. Inhibition of p38 MAP Kinase by utilizing a novel allostericbinding site. Nat Struct Biol, 2002, 9(4): 268–272
	Kuma Y, Sabio G, Bain J, Shpiro N, Marquez R, Cuenda A. BIRB796 inhibits all p38 MAPK isoforms in vivo and invivo. J Biol Chem, 2005, 280(20): 19472–19479
	Nishimoto S, Nishida E. MAPKsignaling: ERK5 versus ERK1/2. EMBO Rep, 2006, 7(8): 782–786
	Davies S P, Reddy H, Caivano M, Cohen P. Specificityand mechanism of action of some commonly used protein kinase inhibitors. Biochem J, 2000, 351(1): 95–105
	Gaestel M. MAPKAP kinases– MKs– two's company, three's a crowd. Nat Rev Mol Cell Biol, 2006, 7(2): 120–130
	Noble M E, Endicott J A, Johnson L N. Protein kinase inhibitors:insights into drug design from structure. Science, 2004, 303(5665): 1800–1805
	Force T, Kuida K, Namchuk M, Parang K, Kyriakis J M. Inhibitors of protein kinasesignaling pathways: emerging therapies for cardiovascular disease. Circulation, 2004, 109(10): 1196–1205
	Wang Z, Harkins P C, Ulevitch R J, Han J, Cobb M H, Goldsmith E J. The structure of mitogen-activatedprotein kinase p38 at 2.1Å resolution. Proc Natl Acad Sci U S A, 1997, 94(6): 2327–2332
	Wang Z, Canagarajah B J, Boehm J C, Kassisa S, Cobb M H, Young P R, Abdel-Mequid S, Adams J L, Goldsmith E J. Structural basis of inhibitor selectivity in MAP kinases. Structure, 1998, 6(9): 1117–1128
	Eyers P A, Craxton M, Morrice N, Cohen P, Goedert M. Conversionof SB 203580-insensitive MAP kinase family members to drug-sensitiveforms by a single amino-acid substitution. Chem Biol, 1998, 5(6): 321–328
	Gum R J, McLaughlin M M, Kumar S, Wang Z, Bower M J, Lee J C, Adams J L, Livi G P, Goldsmith E J, Young P R. Acquisitionof sensitivity of stress-activated protein kinase to the p38 inhibitor,SB 203580, by alteration of one or more amino acids within the ATPbinding pocket. J Biol Chem, 1998, 273(25): 15605–15610
	Lisnock J, Tebben A, Frantz B, O’Neill E A, Croft G, O’Keefe S J, Li B, Hacker C, de Laszlo S, Smith A, Libby B, Liverton N, Hermes J, LoGrasso P. Molecular basis for p38 proteinkinase inhibitor specificity. Biochemistry, 1998, 37(47): 16573–16581 doi: 10.1021/bi981591x
	Sack J S, Kish K F, Pokross M, Xie D, Duke G J, Tredup J A, Kiefer S E, Newitt J A. Structural basis for thehigh-affinity binding of pyrrolotriazine inhibitors of p38 MAP kinase. Acta Crystallogr D Biol Crystallogr, 2008, 64(7): 705–710 doi: 10.1107/S0907444908010032
	Abraham R T, Acquarone M, Andersen A, Asensi A, Belle R, Berger F, Berqounioux C, Brunn G, Buquet-Fagot C, Fagot D. Cellular effectsof olomoucine, an inhibitor of cyclin-dependent kinase. Biol Cell, 1995, 83(2―3): 105–120 doi: 10.1016/0248-4900(96)81298-6
	Akella R, Moon T M, Goldsmith E J. Unique MAP kinase bindingsites. Biochim Biophys Acta, 2008, 1784(1): 48–55
	Heo Y S, Kim S K, Seo C I, Kim Y K, Sung B J, Lee H S, Lee J I, Park S Y, Kim J H, Hwang K Y, Hyun Y L, Jeon Y H, Ro S, Cho J M, Lee T G, Yang C H. Structural basis for the selective inhibition of JNK1 by the scaffoldingprotein JIP1 and SP600125. EMBO J, 2004, 23(11): 2185–2195 doi: 10.1038/sj.emboj.7600212
	Salh B. c-Jun N-terminal kinases as potential therapeutic targets. Expert Opin Ther Targets, 2007, 11(10): 1339–1353 doi: 10.1517/14728222.11.10.1339
	Allen L F, Sebolt-Leopold J, Meyer M B. CI-1040 (PD184352), a targetedsignal transduction inhibitor of MEK (MAPKK). Semin Oncol, 2003, 30(5 suppl 16): 105–116 doi: 10.1053/j.seminoncol.2003.08.012
	Shaw D, Wang S M, Villasenor A G, Tsing S, Walter D, Browner M F, Barnett J, Kuqlstatter A. Thecrystal structure of JNK2 reveals conformational flexibility in theMAP kinase insert and indicates its involvement in the regulationof catalytic activity. J Mol Biol, 2008, 383(4): 885–893 doi: 10.1016/j.jmb.2008.08.086
	Anqell R M, Anqell T D, Bamborough P, Bamford M J, Chung C W, Cockerill S G, Flack S S, Jones K L, Laine D I, Longstaff T, Ludbrook S, Pearson R, Smith K J, Smee P A, Somers D O, Walker A L. Biphenyl amide p38 kinaseinhibitors 4: DFG-in and DFG-out binding modes. Bioorg Med Chem Lett, 2008, 18(15): 4433–4437 doi: 10.1016/j.bmcl.2008.06.028
	Moss N, Breitfelder S, Betageri R, Cirillo P F, Fadra T, Hickey E R, Kirrane T, Kroe R R, Madwed J, Nelson R M, Pargellis C A, Qian K C, Regan J, Swinamer A, Torcellini C. Newmodifications to the area of pyrazole-naphthyl urea based p38 MAPkinase inhibitors that bind to the adenine/ATP site. Bioorg Med Chem Lett, 2007, 17(15): 4242–4247 doi: 10.1016/j.bmcl.2007.05.042
	Grande M T, López-Novoa J M. Therapeutical relevance of MAP-kinase inhibitors in renal diseases:current knowledge and future clinical perspectives. Curr Med Chem, 2008, 15(20): 2054–2070 doi: 10.2174/092986708785132889
	Sebolt-Leopold J S. Development of anticancer drugs targetingthe MAP kinase pathway. Oncogene, 2000, 19(56): 6594–6599 doi: 10.1038/sj.onc.1204083
	Malemud C J. Inhibitors of stress-activated protein/mitogen-activatedprotein kinase pathways. Curr Opin Pharmacol, 2007, 7(3): 339–343 doi: 10.1016/j.coph.2006.11.012
	Gollob J A, Wilhelm S, Carter C, Kelley S L. Role of Raf kinase in cancer: therapeutic potential oftargeting the Raf/MEK/ERK signal transduction pathway. Semin Oncol, 2006, 33(4): 392–406 doi: 10.1053/j.seminoncol.2006.04.002
	Roberts P J, Der C J. Targetingthe Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatmentof cancer. Oncogene, 2007, 26(22): 3291–3310 doi: 10.1038/sj.onc.1210422
	Arslan M A, Kutuk O, Basaga H. Protein kinases as drug targets in cancer. Curr Cancer Drug Targets, 2006, 6(7): 623–634 doi: 10.2174/156800906778742479
	Schuh K, Pahl A. Inhibitionof the MAP kinase ERK protects from lipopolysaccharide-induced lunginjury. Biochem Pharmacol, 2009, 77(12): 1827–1834 doi: 10.1016/j.bcp.2009.03.012
	Chung E J, Brown A P, Asano H, Mandler M, Burgan W E, Carter D, Camphausen K, Citrin D. Invivo and in vivo radiosensitizationwith AZD6244 (ARRY-142886), an inhibitor of mitogen-activated proteinkinase/extracellular signal-regulated kinase 1/2 kinase. Clin Cancer Res, 2009, 15(9): 3050–3057 doi: 10.1158/1078-0432.CCR-08-2954
	Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M, Carter C. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumorangiogenesis, and induces tumor cell apoptosis in hepatocellular carcinomamodel PLC/PRF/5. Cancer Res, 2006, 66(24): 11851–11858 doi: 10.1158/0008-5472.CAN-06-1377
	Apostol B L, Simmons D A, Zuccato C, Illes K, Pallos J, Conforti P, Ramos C, Roarke M, Kathuria S, Cattaneo E, Marsh J L, Thompson L M. CEP-1347 reduces mutant huntingtin-associatedneurotoxicity and restores BDNF levels in R6/2 mice. Mol Cell Neurosci, 2008, 39(1): 8–20 doi: 10.1016/j.mcn.2008.04.007
	de Borst M H, Prakash J, Sandovici M, Klok P A, Hamming I, Kok R J, Navis G, van Goor H. c-JunNH2-terminal kinase is crucially involved in renal tubule-interstitialinflammation. J Pharmacol Exp Ther, 2009, 331(3): 896–905 doi: 10.1124/jpet.109.154179
	Carboni S, Boschert U, Gaillard P, Gotteland J P, Gillon J Y, Vitte P A. AS601245, a c-Jun NH2-terminalkinase (JNK) inhibitor, reduces axon/dendrite damage and cognitivedeficits after global cerebral ischemia in gerbils. Br J Pharmacol, 2008, 153(1): 157–163 doi: 10.1038/sj.bjp.0707574
	Barone F C, Irving E A, Ray A M, Lee J C, Kassis S, Kumar S, Badger A M, Legos J J, Erhardt J A, Ohlstein E H, Hunter A J, Harrison D C, Philpott K, Smith B R, Adams J L, Parsons A A. Inhibition of p38 mitogen-activated protein kinase provides neuroprotectionin cerebral focal ischemia. Med Res Rev, 2001, 21(2): 129–145 doi: 10.1002/1098-1128(200103)21:2<129::AID-MED1003>3.0.CO;2-H
	Medicherla S, Fitzgerald M F, Spicer D, Woodman P, Ma J Y, Kapoun A M, Chakaravaty S, Dugar S, Protter A A, Higgins L S. p38alpha-selective mitogen-activated protein kinase inhibitor SD-282reduces inflammation in a subchronic model of tobacco smoke-inducedairway inflammation. J Pharmacol Exp Ther, 2008, 324(3): 921–929 doi: 10.1124/jpet.107.127092
	Genovese M C. Inhibition of p38: has the fat lady sung? Arthritis Rheum, 2009, 60(2): 317–320 doi: 10.1002/art.24264
	Tripathi B K, Stepp M A, Gao C Y, Zelenka P S. The Cdk5 inhibitor olomoucine promotes corneal debridement woundclosure in vivo. Mol Vis, 2008, 14(1): 542–549
	Bogoyevitch M A, Boehm I, Oakley A, Ketterman A J, Barr R K. Targeting the JNK MAPK cascadefor inhibition: basic science and therapeutic potential. Biochim Biophys Acta, 2004, 1697(1―2): 89–101
	Hall-Jackson C A, Goedert M, Hedge P, Cohen P. Effect of SB203580 on the activity of c-Raf in vitroand in vivo. Oncogene, 1999, 18(12): 2047–2054 doi: 10.1038/sj.onc.1202603
	Katsanakis K D, Owen C, Zoumpourlis V. JNK and ERK signaling pathwaysin multistage mouse carcinogenesis: studies in the inhibition of signalingcascades as a means to understand their invivo biological role. AnticancerRes, 2002, 22(2A): 755–759

[1]	Xueling Suo, Du Lei, Wenbin Li, Lei Li, Jing Dai, Song Wang, Nannan Li, Lan Cheng, Rong Peng, Graham J Kemp, Qiyong Gong. Altered white matter microarchitecture in Parkinson’s disease: a voxel-based meta-analysis of diffusion tensor imaging studies[J]. Front. Med., 2021, 15(1): 125-138.
[2]	Jing Ma, Shiyu Chen, Lili Hao, Wei Sheng, Weicheng Chen, Xiaojing Ma, Bowen Zhang, Duan Ma, Guoying Huang. Long non-coding RNA SAP30-2:1 is downregulated in congenital heart disease and regulates cell proliferation by targeting HAND2[J]. Front. Med., 2021, 15(1): 91-100.
[3]	Yong Fan, Yan Geng, Lin Shen, Zhuoli Zhang. Advances on immune-related adverse events associated with immune checkpoint inhibitors[J]. Front. Med., 2021, 15(1): 33-42.
[4]	Xiaofang Cai, Hanlan Jiang, Simin Zhang, Shengying Xia, Wenhui Du, Yaoling Ma, Tao Yu, Wenbin Li. Clinical manifestations and pathogen characteristics in children admitted for suspected COVID-19[J]. Front. Med., 2020, 14(6): 776-785.
[5]	Ching-Hon Pui. Precision medicine in acute lymphoblastic leukemia[J]. Front. Med., 2020, 14(6): 689-700.
[6]	Lingling Tang, Yingan Jiang, Mengfei Zhu, Lijun Chen, Xiaoyang Zhou, Chenliang Zhou, Peng Ye, Xiaobei Chen, Baohong Wang, Zhenyu Xu, Qiang Zhang, Xiaowei Xu, Hainv Gao, Xiaojun Wu, Dong Li, Wanli Jiang, Jingjing Qu, Charlie Xiang, Lanjuan Li. Clinical study using mesenchymal stem cells for the treatment of patients with severe COVID-19[J]. Front. Med., 2020, 14(5): 664-673.
[7]	Huiwen Ren, Can Wu, Ying Shao, Shuang Liu, Yang Zhou, Qiuyue Wang. Correlation between serum miR-154-5p and urinary albumin excretion rates in patients with type 2 diabetes mellitus: a cross-sectional cohort study[J]. Front. Med., 2020, 14(5): 642-650.
[8]	Jiuyang Xu, Chaolin Huang, Guohui Fan, Zhibo Liu, Lianhan Shang, Fei Zhou, Yeming Wang, Jiapei Yu, Luning Yang, Ke Xie, Zhisheng Huang, Lixue Huang, Xiaoying Gu, Hui Li, Yi Zhang, Yimin Wang, Frederick G. Hayden, Peter W. Horby, Bin Cao, Chen Wang. Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis[J]. Front. Med., 2020, 14(5): 601-612.
[9]	Zhengqian Li, Taotao Liu, Ning Yang, Dengyang Han, Xinning Mi, Yue Li, Kaixi Liu, Alain Vuylsteke, Hongbing Xiang, Xiangyang Guo. Neurological manifestations of patients with COVID-19: potential routes of SARS-CoV-2 neuroinvasion from the periphery to the brain[J]. Front. Med., 2020, 14(5): 533-541.
[10]	Joseph JY Sung, Nicholas CH Poon. Artificial intelligence in gastroenterology: where are we heading?[J]. Front. Med., 2020, 14(4): 511-517.
[11]	Xiaojing Jiao, Dong Zhang, Quan Hong, Lei Yan, Qiuxia Han, Fengmin Shao, Guangyan Cai, Xiangmei Chen, Hanyu Zhu. Netrin-1 works with UNC5B to regulate angiogenesis in diabetic kidney disease[J]. Front. Med., 2020, 14(3): 293-304.
[12]	Amy Lee, Fa-Chyi Lee. Medical oncology management of advanced hepatocellular carcinoma 2019: a reality check[J]. Front. Med., 2020, 14(3): 273-283.
[13]	Min Zhou, Xinxin Zhang, Jieming Qu. Coronavirus disease 2019 (COVID-19): a clinical update[J]. Front. Med., 2020, 14(2): 126-135.
[14]	Zhiruo Zhang, Shelan Liu, Mi Xiang, Shijian Li, Dahai Zhao, Chaolin Huang, Saijuan Chen. Protecting healthcare personnel from 2019-nCoV infection risks: lessons and suggestions[J]. Front. Med., 2020, 14(2): 229-231.
[15]	Shuxian Zhang, Zezhou Wang, Ruijie Chang, Huwen Wang, Chen Xu, Xiaoyue Yu, Lhakpa Tsamlag, Yinqiao Dong, Hui Wang, Yong Cai. COVID-19 containment: China provides important lessons for global response[J]. Front. Med., 2020, 14(2): 215-219.

Viewed

Full text

Abstract

Cited

Shared

Discussed